Myeloma Minute: Latest on Myeloma Risk Factors
| INNOVATION | Latest Research New Studies Point to Increased Risk of MGUS in Firefighters Exposed to 9/11 CarcinogensFirefighters who responded to the World Trade Center terrorist attack are twice as likely to develop the myeloma precursor state MGUS. This and other research news, says IMF Chairman Dr. Brian G.M. Durie, underscore the fact that “our environment and our bodies are in a delicate balance of biochemical reactions that must be protected from dramatic shifts.” |
|
| EDUCATION | For Patients Patients Can Now Listen to Excerpts from This Ask Dr. Durie Doctors’ EditionNow available from Medscape Oncology are excerpts from a CME (continuing medical education) activity for hematologists and oncologists moderated by International Myeloma Foundation Chairman Brian G.M. Durie, MD. The first videos focus on “Proteasome Inhibitors in Multiple Myeloma.” Myeloma experts Shaji Kumar, MD; Thomas Martin, MD; Joseph Mikhael, MD; and Saad Usmani, MD; provide expert insights to improve selection of proteasome inhibitor-based therapy for patients with multiple myeloma. Patients can now learn from these educational videos as well. |
|
| INSPIRATION | Mother's Day |
| INSPIRATION | Myeloma Voices |
Shop Amazon This Mother’s Day and Give to the IMF at the Same Time |
For Myeloma Patient Daniel Neidert, “Knowledge Is Power” |
Whether you shop Amazon this Mother’s Day (Sunday, May 13th) or for your daily needs, please bookmark amazon.myeloma.org. When you shop at this link, Amazon will donate a percentage of your total purchase to the IMF, at no added cost to you. Donating to the IMF this Mother’s Day is as easy as a point-and-click. |
Dan Neidert was diagnosed with multiple myeloma in 2013. After an unsuccessful transplant, he was put on a different treatment regimen. Since then, he has been living symptom-free. Dan now advises, “The more knowledge you have, the better you are going to be. As a patient, you will definitely have better outcomes because you will be able to decide what’s best going forward.” Watch Dan’s story about his journey of living with myeloma. |
| EDUCATION | Myeloma Today Hot Off the Press: Myeloma TodayThis quarter’s Myeloma Today journal is available free to download as a pdf! You can also receive a free printed copy in the mail. The Spring edition includes a discussion of antibody therapies in myeloma, as well as the expanded approval of Xgeva® and news on the use of Darzalex®, Kyprolis®, Pomalyst®, and selinexor. |
|
| EDUCATION | Translations Scientific & Clinical News in Multiple LanguagesDid you know that important medical articles from the IMF’s Myeloma Today journal are available in French, Italian, German, and Spanish? Visit our International Publications library today. |
|
| INNOVATION | Research Grant Calling All Researchers: Submit Your Grant Applications!The Brian D. Novis Research Grants honor the IMF’s founder Brian Novis, who passed of multiple myeloma in July of 1992. The grants are awarded to researchers in the field of multiple myeloma and related disorders including smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), and immunoglobulin-derived amyloidosis. The 2019 grants will fund senior research projects with $80,000 each and junior research projects with $50,000 each. The deadline for applications is Wednesday, August 1, 2018. |
|
| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series |
|
CLINICAL TRIALS |
EVENTS |
New isatuximab Clinical Trial: the IMROZ Study New isatuximab Clinical Trial: the IKEMA Study New ixazomib Clinical Trials: Learn How to Participate Join the conversation about myeloma on the Smart Patients Message Board |
May 5-6, 2018 May 12, 2018 June 2, 2018 June 9, 2018
|
Amgen, Celgene Corporation, Genentech, Janssen Oncology, and Takeda Oncology
and individuals like you who supported the IMF this year